AAAAAA
Results:
1-15
|
Results: 15
Authors:
Dalbagni, G
Ren, ZP
Herr, H
Cordon-Cardo, C
Reuter, V
Citation: G. Dalbagni et al., Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinalstudy, CLIN CANC R, 7(9), 2001, pp. 2797-2801
Authors:
Eschwege, P
de Ledinghen, V
Camilli, T
Kulkarni, S
Dalbagni, G
Droupy, S
Jardin, A
Benoit, G
Weksler, BB
Citation: P. Eschwege et al., Cyclooxygenase-2: a new target for epithelial cancer treatments - Arachidonic acid and prostaglandins, inflammation and oncology, PRESSE MED, 30(10), 2001, pp. 508-510
Authors:
Eschwege, P
de Ledinghen, V
Camilli, T
Kulkarni, S
Dalbagni, G
Droupy, S
Jardin, A
Benoit, G
Weksler, BB
Citation: P. Eschwege et al., Cyclooxygenase-2: a new target for epithelial cancer treatments - Cyclooxygenases, PRESSE MED, 30(10), 2001, pp. 511-514
Authors:
Eschwege, P
de Ledinghen, V
Camilli, T
Kulkarni, S
Dalbagni, G
Droupy, S
Jardin, A
Benoit, G
Weksler, BB
Citation: P. Eschwege et al., Cyclooxygenase-3: a new target far epithelial cancer treatments - Cyclooxygenase inhibitors, PRESSE MED, 30(10), 2001, pp. 515-517
Authors:
Dalbagni, G
Donat, SM
Eschwege, P
Herr, HW
Zelefsky, MJ
Citation: G. Dalbagni et al., Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra, J UROL, 166(5), 2001, pp. 1759-1761
Authors:
Dalbagni, G
Genega, E
Hashibe, M
Zhang, ZF
Russo, P
Herr, H
Reuter, V
Citation: G. Dalbagni et al., Cystectomy for bladder cancer: A contemporary series, J UROL, 165(4), 2001, pp. 1111-1116
Authors:
Dalbagni, G
Cordon-Cardo, C
Sheinfeld, J
Citation: G. Dalbagni et al., Current prospects for the use of molecular markers in treatment of bladdercancer by cystectomy or bladder-conserving approaches, CURR CLIN U, 2001, pp. 381-392
Current use and questions concerning intravesical bladder cancer group forsuperficial bladder cancer
Authors:
Dalbagni, G
Herr, HW
Citation: G. Dalbagni et Hw. Herr, Current use and questions concerning intravesical bladder cancer group forsuperficial bladder cancer, UROL CLIN N, 27(1), 2000, pp. 137
Authors:
Rabbani, F
Richon, VM
Orlow, I
Lu, ML
Drobnjak, M
Dudas, M
Charytonowicz, E
Dalbagni, G
Cordon-Cardo, C
Citation: F. Rabbani et al., Prognostic significance of transcription factor E2F-1 in bladder cancer: Genotypic and phenotypic characterization, J NAT CANC, 91(10), 1999, pp. 874-881
Authors:
Cozzi, PJ
Bajorin, DF
Tong, W
Nguyen, H
Scott, J
Heston, WDW
Dalbagni, G
Citation: Pj. Cozzi et al., Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinicalstudy in dogs, CLIN CANC R, 5(9), 1999, pp. 2629-2637
Authors:
Dalbagni, G
Zhang, ZF
Lacombe, L
Herr, HW
Citation: G. Dalbagni et al., Male urethral carcinoma: Analysis of treatment outcome, UROLOGY, 53(6), 1999, pp. 1126-1132
Authors:
Dalbagni, G
Rechtschaffen, T
Herr, HW
Citation: G. Dalbagni et al., Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy?, J UROL, 162(3), 1999, pp. 708-709
Authors:
Weinstein, RP
Genega, EM
Dalbagni, G
Citation: Rp. Weinstein et al., Splenosis mimicking transitional cell carcinoma, J UROL, 161(4), 1999, pp. 1281-1281
Authors:
Rabbani, F
Dalbagni, G
Bastar, A
Fair, WR
Citation: F. Rabbani et al., Nomograms to predict pathologic results of radical prostatectomy: Effect of neoadjuvant hormone therapy, MOL UROL, 2(3), 1998, pp. 143-150
Authors:
Dalbagni, G
Zhang, ZF
Lacombe, L
Herr, HW
Citation: G. Dalbagni et al., Female urethral carcinoma: an analysis of treatment outcome and a plea fora standardized management strategy, BR J UROL, 82(6), 1998, pp. 835-841
Risultati:
1-15
|